GSK tar­gets a new in­di­ca­tion for Nu­cala, flags PhI­II suc­cess for a rare dis­ease

Glax­o­SmithK­line may soon have a new mar­ket for its asth­ma drug Nu­cala (mepolizum­ab). The phar­ma gi­ant says that their Phase III study of the drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.